Dépôt numérique

Multiomics profiling of longitudinal melanoma specimens unravels molecular mechanisms of resistance to sequential targeted and cancer immunotherapies

Lee, Jinho, Labrie, Marilyne, Yong, Gen, Camp, Todd, Ma, Hongli, Grout, Megan, Xu, Wei, Beasley, Georgia, Schuchter, Lynn Mara, McGettigan, Suzanne, O'Rourke, Donald M, Herlyn, Meenhard, Corless, Christopher L, Mills, Gordon B et Zhang, Gao (2020). Multiomics profiling of longitudinal melanoma specimens unravels molecular mechanisms of resistance to sequential targeted and cancer immunotherapies In: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), May 29-31, 2020, virtuel.

Ce document n'est pas hébergé sur EspaceINRS.


Background: We evaluated spatially-resolved protein profiling of longitudinal tumor specimens derived from two patients with metastatic melanoma who progressed on sequential therapies including targeted therapy (TT) and immune checkpoint blockade (ICB) therapy targeting T cell-surface antigens (CTLA-4 and PD-1). The purpose of this study was to identify molecular determinants of resistance to sequential TT and ICB therapies. Methods: We performed multiplexed and multidimensional spatial protein profiling using NanoString’s GeoMx Digital Spatial Profiling (DSP) platform and single-cell level imaging analysis with Cyclic Immunofluorescence (CycIF) to simultaneously determine dynamic changes in tumor intrinsic signaling pathways and immune response in the tumor microenvironment (TME). Results: The first patient presented with a BRAFV600E-positive brain metastasis. This patient was sequentially treated with ipilimumab (Ipi), the combination of dabrafenib and trametinib, and pembrolizumab (Pembro) and progressed despite of high expression of CD56 NK cell after all treatments. In addition, CycIF analysis revealed drug resistance in a subpopulation of cells that had continued activation of mTOR (pS6) and EGFR pathways. The second patient presented with dermal metastases on the flank with NRASQ61K mutation. This patient was sequentially treated with Pembo, Talimogene Laherparepvec, the combination of Ipi plus nivolumab, and two different investigational agents combined with Pembro. This patient displayed stable disease (SD) on Pembro but eventually progressed on the subsequent therapies. DSP analysis demonstrated CD68/CD40 myeloid cell infiltrates as well as HLA-DR and CD44 in the TME after the last treatment. CycIF analysis revealed dynamic changes in tumoral characteristics including DNA damage and proliferation during treatment. Furthermore, the analysis suggested that there might be a resistant subpopulation in the last tumor biopsy, which is in line with progression of the disease. Conclusions: In this study, we conducted detailed analyses on serial specimens from two patients to precisely define the spatial distribution of immune responses and cancer signaling pathways. The findings propose that concurrent proteomics analysis and immune monitoring of longitudinal tumor biopsies can be informative in clinical evaluation in order to identify salvage therapies to overcome drug resistance.

Type de document: Document issu d'une conférence ou d'un atelier
Informations complémentaires: Journal of Clinical Oncology 38:15(supll) e22015
Mots-clés libres: -
Centre: Centre INRS-Institut Armand Frappier
Date de dépôt: 30 juin 2022 13:57
Dernière modification: 30 juin 2022 13:57
URI: https://espace.inrs.ca/id/eprint/12370

Actions (Identification requise)

Modifier la notice Modifier la notice